Convatec to launch nitric oxide product as analysts highlight resilience

UK-listed medtech Convatec (LSE: CTEC) plans to launch its new wound care technology, ConvaNiox (nitric oxide), later this year, aiming to strengthen its portfolio in the chronic care market.

ConvaNiox, described by Convatec as the first nitric oxide-generating multimodal dressing for wound care, will initially target diabetic foot ulcers. The company said it plans a staged launch in France, Germany, Italy, Poland, Spain, and the UK, pending regulatory approval, before expanding to other markets.

In clinical testing, ConvaNiox helped wounds heal three times faster and improved healing rates by 60% compared to standard treatments. Convatec acquired the underlying technology through its 2023 purchase of 30 Technology’s anti-infective nitric oxide platform.